Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA) - Overview
Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA) - Companies Involved in Therapeutics Development
Advent Therapeutics Inc
Avecho Biotechnology Ltd
Galephar Pharmaceutical Research Inc
Io Therapeutics Inc
Novartis AG
Orphagen Pharmaceuticals Inc
Orphanix GmbH
Ortho Dermatologics Inc
Polaryx Therapeutics Inc
Selphagy Therapeutics Inc
Sunny BioDiscovery Inc
TherapyX Inc
Toko Pharmaceutical Industries Co Ltd
Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA) - Drug Profiles
(benzoyl peroxide + tretinoin) - Drug Profile
Product Description
Mechanism Of Action
History of Events
(gemfibrozil + tretinoin) - Drug Profile
Product Description
Mechanism Of Action
History of Events
(TPX-6001 + tretinoin) - Drug Profile
Product Description
Mechanism Of Action
History of Events
alitretinoin - Drug Profile
Product Description
Mechanism Of Action
History of Events
alitretinoin - Drug Profile
Product Description
Mechanism Of Action
History of Events
IRX-5183 - Drug Profile
Product Description
Mechanism Of Action
History of Events
OR-812 - Drug Profile
Product Description
Mechanism Of Action
History of Events
SBD-073 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecule to Agonize RAR Alpha and RXR Alpha for Acute Promyelocytic Leukemia - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecules to Antagonize RAR Alpha for Opthamology - Drug Profile
Product Description
Mechanism Of Action
History of Events
tamibarotene - Drug Profile
Product Description
Mechanism Of Action
History of Events
tazarotene - Drug Profile
Product Description
Mechanism Of Action
History of Events
tretinoin - Drug Profile
Product Description
Mechanism Of Action
History of Events
tretinoin - Drug Profile
Product Description
Mechanism Of Action
History of Events
vitamin A palmitate - Drug Profile
Product Description
Mechanism Of Action
History of Events
vitamin A palmitate - Drug Profile
Product Description
Mechanism Of Action
History of Events
Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA) - Dormant Products
Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA) - Discontinued Products
Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA) - Product Development Milestones
Featured News & Press Releases
Aug 03, 2022: Syros receives positive opinion on orphan drug desigtion from the European Medicines Agency for tamibarotene for the treatment of MDS
Feb 02, 2022: Syros receives FDA Orphan Drug Desigtion for tamibarotene for the treatment of MDS
Oct 28, 2021: The first and only tazarotene lotion indicated for acne vulgaris in patients 10 years of age and older, ARAZLO now available for patients by prescription across Cada
Oct 19, 2021: Ortho Dermatologics to present new data on ARAZLO at the 2021 Fall Clinical Dermatology Conference
Sep 10, 2021: RaQualia announces milestone payment from Syros
Sep 09, 2021: Syros announces first patient dosed in SELECT-AML-1 trial of Tamibarotene in combition with Venetoclax and Azacitidine in newly diagnosed unfit AML
Aug 04, 2021: Health Cada approves ARAZLO (Tazarotene) Lotion, 0.045%, first such lotion treatment for acne vulgaris
Apr 21, 2021: Ortho Dermatologics to present abstract on ARAZLO (tazarotene) Lotion at 2021 American Academy of Dermatology Annual Meeting
Dec 05, 2020: Syros presents new data from Phase 2 clinical trial of SY-1425 and announces plans to initiate registration-ebling trial in MDS and randomized Phase 2 trial in AML
Nov 04, 2020: Syros to present new data from phase 2 clinical trial of SY-1425 in oral presentations at 62nd ASH annual meeting
Jul 23, 2020: Ortho Dermatologics launches ARAZLO (tazarotene) lotion, 0.045%, in the United States
Jun 23, 2020: Ortho Dermatologics launches ARAZLO (tazarotene) lotion, 0.045%, in the United States
Jan 13, 2020: Ortho Dermatologics announces publication of pivotal phase 3 data on ARAZLO (tazarotene) Lotion, 0.045% in the Jourl of Drugs in Dermatology (JDD)
Jan 12, 2020: Syros announces new update on SY-1425
Dec 19, 2019: FDA approves Ortho Dermatologics’ ARAZLO (Tazarotene) lotion, 0.045%, for acne vulgaris
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Top 10 Indications, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022

List of Tables

List of Tables
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Indications, 2022
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Pipeline by Advent Therapeutics Inc, 2022
Pipeline by Avecho Biotechnology Ltd, 2022
Pipeline by Galephar Pharmaceutical Research Inc, 2022
Pipeline by Io Therapeutics Inc, 2022
Pipeline by Novartis AG, 2022
Pipeline by Orphagen Pharmaceuticals Inc, 2022
Pipeline by Orphanix GmbH, 2022
Pipeline by Ortho Dermatologics Inc, 2022
Pipeline by Polaryx Therapeutics Inc, 2022
Pipeline by Selphagy Therapeutics Inc, 2022
Pipeline by Sunny BioDiscovery Inc, 2022
Pipeline by TherapyX Inc, 2022
Pipeline by Toko Pharmaceutical Industries Co Ltd, 2022
Dormant Products, 2022
Dormant Products, 2022 (Contd..1)
Discontinued Products, 2022